Saroglitazar
Based on 10 publication(s) in Google Scholar
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.38%
- CAS No.: 495399-09-2
- Formule: C25H29NO4S
- Masse moléculaire:439.57
-
Stockage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Rare Diseases Drug Library
HY-L102
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) Saroglitazar
More- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Sci Adv. 2025 Sep 26;11(39):eads3731. [Abstract]
- Cell Biol Toxicol. 2021 Apr;37(2):293-311. [Abstract]
- Ann Med. 2025 Dec;57(1):2497112. [Abstract]
- iScience. 2025 Apr 3;28(5):112344. [Abstract]
- BMC Complement Med Ther. 2021 Apr 10;21(1):118. [Abstract]
- Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
- SSRN. 2024 May 30.
- Patent. US20210275504A1.
- Patent. US20190388398A1.
Customer Validation & Images
-
Histological Imaging/Staining
-
IF
-
WB
-
RT-PCR
-
ELISA
Activité biologique
|
PPARα 0.65 pM (EC50, HepG2 cell) |
PPARγ 3 nM (EC50, HepG2 cell) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 495399-09-2
-
Appearance Oil
-
Masse moléculaire 439.57
-
Formule C25H29NO4S
-
Color Yellow to brown
-
SMILES
OC([C@@H](OCC)CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334 -
Sci Adv
Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction. [Abstract]2025 Sep 26;11(39):eads3731. PMID: 41004576 -
Cell Biol Toxicol
2021 Apr;37(2):293-311. PMID: 32613381 -
Ann Med
PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis. [Abstract]2025 Dec;57(1):2497112. PMID: 40289698 -
iScience
2025 Apr 3;28(5):112344. PMID: 40276762 -
BMC Complement Med Ther
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway. [Abstract]2021 Apr 10;21(1):118. PMID: 33838689 -
Medicina (Kaunas)
Saroglitazar Ameliorates Pulmonary Fibrosis Progression in Mice by Suppressing NF-κB Activation and Attenuating Macrophage M1 Polarization. [Abstract]2025 Jun 26;61(7):1157. PMID: 40731787
Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
HE staining of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
IF staining of collagen 1 of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
Western blot analysis of lung tissue of control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
PCR analysis of IL-1β, IL-6, and TNF-α in RAW264.7 treated with BLM and SGZ (10 μM).
Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
ELISA analysis of IL-1β, IL-6, and TNF-α of RAW264.7 treated with BLM and SGZ (10 μM).
-
-
-
Solvant et solubilité
DMSO : 50 mg/mL (113.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage[1].
Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3,1, and 3 mg/kg per day) or pioglitazone (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, free fatty acid (FFA), and insulin levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2750 mL | 11.3748 mL | 22.7495 mL | 56.8738 mL |
| 5 mM | 0.4550 mL | 2.2750 mL | 4.5499 mL | 11.3748 mL | |
| 10 mM | 0.2275 mL | 1.1375 mL | 2.2750 mL | 5.6874 mL | |
| 15 mM | 0.1517 mL | 0.7583 mL | 1.5166 mL | 3.7916 mL | |
| 20 mM | 0.1137 mL | 0.5687 mL | 1.1375 mL | 2.8437 mL | |
| 25 mM | 0.0910 mL | 0.4550 mL | 0.9100 mL | 2.2750 mL | |
| 30 mM | 0.0758 mL | 0.3792 mL | 0.7583 mL | 1.8958 mL | |
| 40 mM | 0.0569 mL | 0.2844 mL | 0.5687 mL | 1.4218 mL | |
| 50 mM | 0.0455 mL | 0.2275 mL | 0.4550 mL | 1.1375 mL | |
| 60 mM | 0.0379 mL | 0.1896 mL | 0.3792 mL | 0.9479 mL | |
| 80 mM | 0.0284 mL | 0.1422 mL | 0.2844 mL | 0.7109 mL | |
| 100 mM | 0.0227 mL | 0.1137 mL | 0.2275 mL | 0.5687 mL |
Saroglitazar Related Classifications
HY-19937 Related Classifications
Powered by Bioz